Skip to content
Back to Feed
Seed

MindSpire secures £1m in seed funding to advance its neurotechnology platform

The company will use the capital to develop artificial intelligence capabilities and expand its clinical research partnerships.

£1.0MSeed

Share allotment filed at Companies House

MindSpire is a British neurotechnology venture that develops wearable consumer devices and software for personal wellbeing and vagus nerve stimulation.

MindSpire, the British neurotechnology business behind the Sona ear-worn vagus nerve stimulation device, has secured £1m in fresh seed financing. Backing for the round comes from institutional investors SFC Capital and SyndicateRoom, alongside participation from a cohort of angel investors.

The capital arrives as the company scales its operations following extensive real-world usage of its wearable device. MindSpire intends to direct the proceeds towards enhancing its software platform with artificial intelligence, driving product development, and deepening its academic and clinical collaborations.

The latest raise builds on earlier institutional funding secured by the London-headquartered firm, which combines non-invasive nerve stimulation with physiological feedback to support everyday stress management and sleep wellbeing.


From the founder

"Bringing SONA to market has given us a growing real-world picture of how differently people respond to stimulation. The 40,000 sessions show why relying on a single measure is not enough. This next phase will bring together richer physiological data, AI and clinical research to develop protocols that are more personalised, adaptive and evidence-led."
Jane Ollis

Jane Ollis

Founder and President at MindSpire


Investor perspective

"SFC Capital is delighted to continue supporting SONA through follow-on funding as the company enters its next phase of growth. The team has made impressive progress in bringing its innovative technology to market, with a wearable device that reads biometric signals and delivers personalised nerve stimulation to help improve sleep and reduce stress. We look forward to seeing SONA scale production and bring its technology to more consumers."
Michael Theodosiou

Michael Theodosiou

Portfolio Manager, SFC


Use of funds

  1. 01Continue product development
  2. 02Fund research and development

Investors

Michael Theodosiou

Michael Theodosiou

SFC

SyndicateRoom

SyndicateRoom


Categories

MedTech

About the company

M

MindSpire

MindSpire develops wearable neurotechnology devices designed to support everyday calm and wellbeing.

London, UK— Founded 2018— Website
£1.9MRaised